Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 extension study in ankylosing spondylitis
NL-OMON36799Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Mar 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of secukinumab in ankylosing spondylitis (AS), sponsored by Novartis. Planned start Mar 2010; status: not yet recruiting.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON36799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36799.